|Bid||0.497 x 1000|
|Ask||0.600 x 1000|
|Day's Range||0.515 - 0.560|
|52 Week Range||0.420 - 3.040|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 29, 2018 - Apr 2, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.25|
Diffusion Pharmaceuticals Inc. (DFFN) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on extending the life expectancy of cancer patients, today announced the validation of European Patent No.: 2 575 487, entitled “Oral Formulations of Bipolar Trans Carotenoids.” This patent is directed to oral formulations of bipolar trans carotenoids including trans sodium crocetinate (“TSC”). Embodiments of the invention include the novel compositions in the form of a tablet, pill or capsule. The claims also include compositions for the treatment of hypoxia caused by many disorders.
In the release issued under the same headline on May 10, 2018 by Diffusion Pharmaceuticals Inc., please note that in the Consolidated Balance Sheets table, Cash and cash equivalents row, under March 31, ...
In early 2018, Diffusion (DFFN) announced the acceptance of an abstract titled “PreHospital Acute Stroke Therapy with Trans Sodium Crocetinate (PHAST-TSC)” to be presented at the International Stroke Conference. The abstract discussed the design and rationale for a planned Phase 2 study of trans sodium crocetinate (TSC), a small molecule that improves diffusion of oxygen through the bloodstream in order to increase tissue oxygenation, in patients with acute ischemic (from a clot) or hemorrhagic (from a bleed) stroke. The Pre-Hospital Ambulance Stroke Trial – TSC (PHAST-T) will be a randomized, double blind, placebo controlled trial with an anticipated enrollment of 160 ambulance-transported patients treated within two hours of the onset of a suspected stroke.
Patient screening and enrollment are underway in Phase 3 inoperable GBM brain cancer trial Key U.S. Patent Issued Clinical trial preparations are ongoing for Phase 2 trial with TSC in stroke CHARLOTTESVILLE, ...
On April 3, 2018, Diffusion Pharmaceuticals, Inc. (DFFN) announced financial results for 2017 and provided a business update. The primary outcome of the study is overall survival at two years between the two groups.
NEW YORK, NY / ACCESSWIRE / April 3, 2018 / Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (''Diffusion'' or ''the Company''), a clinical-stage biotechnology company focused on extending the life expectancy ...
Patient Enrollment in Phase 3 Inoperable GBM Brain Cancer Trial Underway Raised $12 Million in Underwritten Public Offering Preparing to Commence Clinical Trial with TSC in Stroke Expanded Intellectual ...
On January 29, 2018, Diffusion Pharmaceuticals, Inc. (DFFN) announced that the first patient has been dosed in the Phase 3 clinical trial of trans sodium crocetinate (TSC), a small molecule that improves diffusion of oxygen through the bloodstream in order to increase tissue oxygenation and potentially improve outcomes associated with radiation and chemotherapy cancer treatments. The trial has been named INTACT (INvestigating Tsc Against Cancerous Tumors) and is anticipated to screen 300 patients with inoperable glioblastoma multiforme (GBM) and enroll 264 such that results from 236 patients will be available for analysis.
Shares of clinical-stage biotechnology company Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) are crashing – down nearly 40% as of this writing. Diffusion announced this morning that it will be selling at least 15 million shares of its own stock to raise cash for research and development of the company's lead product candidate, transcrocetinate sodium, including clinical trial activities, and for general corporate purposes. Each share of common stock is being sold together with a common warrant to purchase one share of common stock at a combined effective price to the public of $0.80 per share and accompanying common warrant. The common warrants will be exercisable at an exercise price of $0.80 per share and will expire five years from the date of issuance.
NEW YORK, NY / ACCESSWIRE / January 10, 2018 / Diffusion Pharmaceuticals and Pain Therapeutics were two biotech stocks scorching on Tuesday. Shares of Pain Therapeutics even hit a new high after announcing ...
In this article, I’m going to take a look at Diffusion Pharmaceuticals Inc’s (NASDAQ:DFFN) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...
Diffusion Pharmaceuticals Inc (NASDAQ:DFFN), a USD$19.46M small-cap, is a healthcare company operating in an industry, which faces key trends such as rising demand fuelled by an aging population and theRead More...
If you are looking to invest in Diffusion Pharmaceuticals Inc’s (NASDAQ:DFFN), or currently own the stock, then you need to understand its beta in order to understand how it canRead More...
On November 13, 2017, Diffusion Pharmaceuticals, Inc. (DFFN) announced financial results for the third quarter of 2017. As expected, the company did not report any revenues. Diffusion reported net income of $5.1 million, or $0.37 per share, which was the result of a non-cash gain of $8.4 million related to the change in the fair value of warrant liabilities due to a decrease in the fair market value of the company’s common stock and not indicative of ongoing operations.
NEW YORK, NY / ACCESSWIRE / October 18, 2017 / Shares of Neothetics and Diffusion Pharmaceuticals saw big gains in Tuesday trading after the companies had positive news respectively. Neothetics soared ...
Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) is a mover and shaker out on the Street today, with investors sparking the stock on an almost 35% upturn. The US drug discovery and development firm announced that it has received final protocol guidance from the FDA for a Phase 3 clinical trial with the Company’s lead compound trans sodium crocetinate (TSC) in patients newly diagnosed with inoperable glioblastoma multiforme (GBM), a type of brain cancer. The Company has responded to all outstanding points raised by the FDA and plans to begin the trial under the protocol agreed to by the FDA by the end of 2017.